Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Here’s the latest company planning for gene-edited babies The news: A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes ...

Cellectis announced the acceptance of two abstracts for presentation at the ASH 2025 annual meeting, highlighting significant advancements in their clinical trials. The first abstract presents ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

The press release will be available in the Investors section of Cellectis’ website: Cellectis will not host a conference call to discuss these results. Our investors relations team remains available ...

Therapeutics Startup Helex Secures USD 3.5 Mn to Develop Targeted Kidney Treatments Helex, a therapeutics startup focused on genetic kidney diseases, has raised USD 3.5 million in a seed funding round ...

Mary E. Brunkow Ph.D., a 1983 graduate of UW who now works in Seattle, won the Nobel Prize in Physiology or Medicine. News of ...